Ingredient supplier PanTheryx has launched Relesium, a formulation of chicken egg powder and bovine colostrum designed to address gut-related side effects of glucagon-like peptide 1 (GLP-1) medications.
 
Relesium is formulated to support digestive discomfort, which is experienced by a substantial portion of GLP-1 medication users worldwide, the company reports, with up to 50% of users reporting mild to moderate gastrointestinal side effects.
 
Current recommendations include diet modification, but many patients seek additional support to manage symptoms effectively without turning to other medicaitons, PanTheryx reported.
 
“Relesium is entering a largely untapped market addressing a need for an all-natural, fast-acting, and patented solution to alleviate the GI discomfort millions worldwide experience with GLP-1 drugs, while also helping to restore the gut microbiome,” said Tom Feeley, CEO of PanTheryx. “This ingredient now allows health and wellness companies to offer their customers a science-backed product that addresses these challenges without compromising the effectiveness of their GLP-1 therapy and additional medications.”
 
A new publication in Nutrients authored by Raymond Playford, MD, PhD, a gastroenterologist and longstanding scientific advisor at PanTheryx, and professor of molecular medicine at the University of West London, consolidates the growing body of research on chicken egg powder and bovine colostrum. Playford found that both ingredients offer significant gut-stabilizing benefits, particularly when used in combination due to their synergistic effects.
 
“The combination of egg and bovine colostrum not only supports gut stability but also delivers high-quality protein and essential micronutrients – vitamins, minerals, and antioxidants – particularly important for GLP-1 users who may experience reduced appetite, fatigue, and significant energy loss. It also contains prebiotics, to support a healthy microbiome and several other factors such as immunoglobulins and antimicrobial peptides, that help prevent adhesion of microbes to gut surfaces, inhibit bacterial metabolism, and neutralize toxins and viruses,” Playford wrote.
 
PanTheryx also commissioned an observational pilot study led by Harry Oken, MD, an internist and adjunct professor of medicine at the University of Maryland and former chair of the department of medicine at Johns Hopkins Howard County Medical Center, and Michael Roizen, MD, an internist, anesthesiologist, and chief wellness officer emeritus at the Cleveland clinic, to explore the ingredient’s effectiveness among GLP-1 medication users.
 
“The rapid improvements observed with Relesium offer a natural remedy and show strong potential to help patients feel better faster,” said Oken. “By easing gastrointestinal distress and aiding gut health, Relesium enables patients to comfortably and safely take the prescribed dose of GLP-1s in order to achieve their maximum intended benefits.
 
PanTheryx reported that 18 participants using these medications enrolled in the study. Ten of these patients experienced gastrointestinal symptoms and were administered Relesium. The initial results indicated that all ten participants reported notable improvement and reduction in gut-related symptoms after taking Relesium daily, the company reported, and a placebo-controlled clinical trial is planned to validate the ingredient’s efficacy.
 
Relesium is launching in a powder format, which can be used as a standalone supplement or within other product formulations starting in January 2025. Additional formats and formulations are also under development.